Sophiris Bio, Inc. (NasdaqGM:SPHS) will consider acquisitions. Sophiris Bio has filed a shelf registration in the amount of $100 million. Sophiris Bio will use the net proceeds for general corporate purposes, which may include research and development, capital expenditures, working capital and general and administrative expenses.

It may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.